Pain-blocking gene mutation may hold clues for drug developers

Pharmaceutical researchers are studying a mutation in the SCN9A gene that makes patients immune to pain. While medications can mute pain, new experimental formulations that try to mimic the gene mutation aim to stop nerve cells from sending pain signals to the brain.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA